Juno is presently recruiting for any phase 1 trial investigating using its BCMA-directed Vehicle-T cells alongside chemotherapy drug lenalidomide (Revlimid).
“These licenses open an essential method of enhance the activity and outcomes for Vehicle T cells directed at BCMA,” stated Sunil Agarwal, M.D., Juno’s president of development and research, within the statement. “We intend to begin numerous studies in 2018 mixing a gamma secretase inhibitor with this BCMA Vehicle T product candidates.”
Through its agreement with Lilly, Juno will obtain a license to Lilly’s GSI, LY3039478. The handles Fred Hutch and OncoTracker can give Juno exclusive legal rights to ip within the sphere of mixtures of GSIs and BCMA-directed engineered T cells.
Juno Therapeutics, which dumped its lead Vehicle-T enter in March, has inked itself a possible lifeline: a trio of license contracts that can help it create a combo strategy to multiple myeloma.
After that it shifted its focus to a different treatment, that one for relapsed or refractory aggressive B cell non-Hodgkin lymphoma. In June, the biotech reported good results from the phase 1 dose-finding study from the candidate, JCAR017.
The deals, signed with Eli Lilly, OncoTracker and Fred Hutchinson Cancer Research Center, try to boost the introduction of a multiple myeloma therapy mixing BCMA-directed Vehicle-T cells in conjunction with gamma secretase inhibitors (GSIs).
RELATED: Juno executives investigated over trial deaths disclosure legally firm